PhorMed Inc. (PhorMed or Company) has recently filed a Form C to launch a Regulatory CF equity crowdfunding campaign on the WeFunder platform. The campaign can be found at https://wefunder.com/phormed.
PhorMed is a clinical stage biopharmaceutical company that uses cell-repair technology to treat diseases in oncology, inflammation, and neuroscience. The company aims to raise $5 million to support its clinical trials. Currently, the company has three indications in phase II: Acute Myeloid Leukemia (AML), Hodgkin’s Lymphoma (HL), and Acute Respiratory Distress Syndrome (ARDS), as well as one indication in the preclinical phase, Parkinson’s disease (PD).
If the fundraising is successful, PhorMed plans to enroll patients in phase II studies for ARDS and HL, while continuing its preclinical research in PD and ARDS. If additional capital is raised beyond the $5 million goal, the company intends to launch its phase II study in AML.
To date, PhorMed has raised $3.5 million, with $2.75 million coming from two previous equity crowdfunding campaigns on the StartEngine platform, involving over 4,100 investors and generating over 8,800 followers. The company also received $750,000 from an angel investor.
PhorMed continues to collaborate with the clinical site Winship Cancer Institute at Emory University, as well as Contract Research Organizations WuXi Biologics and Absorption Systems for its study drug manufacturing and pre-clinical studies, respectively.
For more information on the crowdfunding campaign, visit https://wefunder.com/phormed and the company’s website at https://www.phormed.com.
Contact: Ben Chang, info@phormed.com
Images:
– Cell Repair Therapy: [Image Link]
– PhorMed Logo: [Image Link]
– Cision: [Image Link]
Original Source: https://www.prnewswire.com/news-releases/phormed-inc-launches-new-regulation-cf-equity-crowdfunding-campaign-on-wefunder-302068445.html
Source: PhorMed
In conclusion, PhorMed Inc’s decision to launch a Regulation CF equity crowdfunding campaign through WeFunder is a strategic move that allows them to raise capital from a wider pool of investors. This innovative approach to fundraising has the potential to drive growth and success for the company in the future.